Recent

% | $
Quotes you view appear here for quick access.

CEL-SCI Corporation Message Board

  • cmegladon cmegladon Feb 18, 2010 11:13 AM Flag

    From form 10K January 2010

    On November 6, 2009, CEL-SCI announced that The Johns Hopkins University School of Medicine has given clearance for CEL-SCI's first clinical study to proceed using LEAPS-H1N1. This study started one week later.

    Read more: http://www.faqs.org/sec-filings/100113/CEL-SCI-CORP_10-K/#ixzz0fu7J3gQx

    This CLEARLY states the study started one week later.It did NOT say "enrollment started".So my question is, did the study start or not due to enrollment issues?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "On November 6, 2009, CEL-SCI announced that The Johns Hopkins University School of Medicine has given clearance for CEL-SCI's first clinical study to proceed using LEAPS-H1N1. This study started one week later."

      Maybe it's not important, but it seems that the tone of this statement is much, much more subdued than the original announcement. There is no mention of JH's Dr. Z. (Zellerman?) who was cited to lead the study.

    • Yesterday, I sold on the bounce and hit for about .20c. As I said was looking to get back in in the .60s.
      I did this AM, twice and was hoping for another dead cat bounce.
      Still am, as there are dozens of biotechs out there with higher valuations and no products.
      My problem is buying on a shareholder letter that on one hand is sent out to address attempts at discrediting the company, and on the other hand, the CEO states his intent is never to address attampts by disingenuous folks who have other agendas....lol
      His history is to write shareholder letters doing just that.
      PR via the use of these shareholder letters, and microcap newsletters has never been taken seriously by Wall Street.
      But nowadays the PPS of a company seems to be propelled higher or knocked down by "legal manipulation" and the use of trading programs, internet marketing etc.
      I'm hopeful this company is now focused on an effort to get enrollment in P III started. That will propel the PPS higher, even if temporarily, and for the CEO to get his shares.
      I think there are a few folks at CVM who have been waiting for their share of the pie.
      I'll ride that wave.

    • November 2009, height of the Flu Season, one of the largest clinics in the U.S., one of the most prestigious medical teaching hospitals in the world doesn't complete a tiny study of H1N1 seeking the blood of 20 H1N1 patients?
      Just tell me that makes sense to you?

    • Of course, the study would not wait for complete enrollment of 20 patients. The condition runs it course on afflicted individuals over the course of days, and can't wait for full enrollment to begin. So the question is, were any patients treated, or blood samples from any patients exposed to the LEAPS process, and were there encouraging results, or neutral, or what? If they don't get to 20, will they ever report on what they did experience with any number of patients? People will draw their own conclusions in the absence of released results.

 
CVM
0.5485-0.0090(-1.61%)1:35 PMEDT